[Salvage therapy in relapsed or refractory malignant lymphoma]
- PMID: 10741149
[Salvage therapy in relapsed or refractory malignant lymphoma]
Abstract
High dose therapy(HDT) followed by autologous stem cell transplantation(ASCT) is a therapeutic options in chemotherapy-sensitive aggressive non-Hodgkin's lymphoma(NHL) and Hodgkin's disease at relapse. Of the patients with NHL, primary refractory disease should also be treated with such therapy. In patients with indolent lymphoma at relapse, disease free survival after treatment with purged ASCT has been shown to reach a plateau, although the therapy is a matter for debate at present. Anti-CD-20 monoclonal antibody in combination with standard- or high-dose chemotherapy is also quite effective for indolent NHL at relapse. In aggressive NHL with high- or high-intermediate international prognostic index, Burkitt's lymphoma, and mantle cell lymphoma. ASCT as front-line therapy might improve the clinical outcome.
Similar articles
-
[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].Ai Zheng. 2006 Apr;25(4):486-9. Ai Zheng. 2006. PMID: 16613686 Chinese.
-
Autologous stem cell transplantation in lymphoma.Semin Hematol. 2007 Oct;44(4):234-45. doi: 10.1053/j.seminhematol.2007.08.007. Semin Hematol. 2007. PMID: 17961722 Review.
-
[Recent progress in the treatment of malignant lymphoma].Gan To Kagaku Ryoho. 2001 Sep;28(9):1213-35. Gan To Kagaku Ryoho. 2001. PMID: 11579632 Review. Japanese.
-
[Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].Gan To Kagaku Ryoho. 2005 Dec;32(13):2059-64. Gan To Kagaku Ryoho. 2005. PMID: 16352929 Japanese.
-
The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.Semin Oncol. 1998 Aug;25(4):503-17. Semin Oncol. 1998. PMID: 9728600 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources